炎症性肠病诊断与治疗的共识意见(2012年·广州)溃疡性结肠炎治疗部分解读

摘要

溃疡性结肠炎(UC)是一种病因尚不十分清楚的慢性非特异性肠道炎症性疾病,近十余年来国内就诊人数呈逐步增加趋势.2012年,中华医学会消化病学分会炎症性肠病(IBD)学组对2007年版中国IBD诊治共识进行了修订.本文以本次共识意见为基础,解读共识意见中建议的精髓,剖析UC治疗中需注意的要点,分层阐述氨基水杨酸制剂、糖皮质激素、免疫抑制剂、生物制剂在UC治疗中的新进展,以期提高临床医师对UC治疗的认知水平.%Ulcerative colitis ( UC) is a chronic non-specific inflammatory disease of the intestine with uncertain etiology. Patients visiting the medical center for UC symptoms are increasing in China during the past decade. The Chinese consensus on diagnosis and management of inflammatory bowel disease (IBD) published in 2007 was revised by IBD study group of Chinese Society of Gastroenterology in Guangzhou, 2012. Based on the new consensus, this article interpreted the essence of the recommendations, dissected the key issues of UC treatment and laid out the new progress in medical treatment such as aminosalicylates, corticosteroids, immunomodulators, and biological agents for helping the clinicians to improve their understanding of UC treatment.